Craig-Hallum raised the firm’s price target on Repligen to $225 from $175 and keeps a Buy rating on the shares. Repligen reproted in line Q4 results and initial FY24 guidance reflects slower than anticipated growth, the analyst tells investors in a research note. The firm believes the company has seen a bottom and will slowly make its way back to its historical growth levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RGEN: